Primary Outcome Measures:
- Characterize the genetic events involved in the development of Wilms' tumor, genitourinary anomalies, hemihypertrophy, and Beckwith-Wiedemann by a combined molecular biology/epidemiologic approach. [ Time Frame: 30 Years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Characterize the genetic events involved in the development of aniridia by a combined molecular biology/epidemiologic approach. [ Time Frame: 30 Years ] [ Designated as safety issue: No ]
Biospecimen Description:
Blood sample(s) for genetic testing. Also, tissue samples, and/or bodily fluids (whether healthy or cancerous) left over from surgeries or procedures performed as part of standard care. The purpose of this clinical research study is to find out why some people develop cancers and tumors, why some families have more cancers than others, and whether certain genes or regions of DNA affect a person's risk of getting cancer.
Researchers sometimes look for causes of cancer or cancer risk by studying the characteristics of certain groups of people, particularly families. This involves collecting medical information and using it to look for a pattern of characteristics which may point to cancer risks. The goal of this study is to use information from blood and tissue samples, as well as medical history, to look for such a pattern.
If you choose to take part in this study, blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time. If this is the case, your doctor will discuss any extra blood draws with you.
You will be asked to complete a questionnaire regarding your medical history and family medical history. The questionnaire will take about 1 hour to complete. You will also be asked to allow members of the study staff to review your medical records. Information in medical records can be used in research to learn about, prevent, or treat cancer.
You will be asked allow members of the study staff to collect any of your tissue (whether healthy or cancerous) that is leftover from surgeries performed as part of your standard care. This applies to any past or future surgical procedures, as well as any tissue being stored in another facility or at UTMDACC. No new surgeries or biopsies will be needed, and no surgical procedures will be performed for research purposes only. This part of the study only has to do with tissue that is left over from your standard procedures and would otherwise be banked or thrown away.
Before your information, tissue samples, and/or bodily fluids can be used for research, the people doing the research must get specific approval from the Institutional Review Board (IRB) of UTMDACC. The IRB is a committee made up of doctors, researchers, and members of the community. The IRB is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. All research done at UTMDACC, including research involving your information, tissue samples, and/or bodily fluids, must first be approved by the IRB.
You will be contacted through 2009, so that the study staff can update your medical history and information.
This is an investigational study. Study procedures will be provided free of charge. About 1500 patients and family members will take part in this study. All will be enrolled at M.D. Anderson.
This protocol is partially funded by a research grant from the National Cancer Institute (NCI).